LOC100041282 Inhibitors
LOC100041282 inhibitors contain compounds such as Imatinib and Erlotinib are tyrosine kinase inhibitors that, by hindering the phosphorylation process, can alter signal transduction cascades with which LOC100041282 might interact. Sirolimus and Venetoclax target mTOR and BCL-2, respectively, affecting cell growth, proliferation, and apoptosis, potentially influencing any role LOC100041282 might have in these processes.
Allopurinol and Zileuton represent inhibitors that affect metabolic enzymes like xanthine oxidase and 5-lipoxygenase, respectively, which could impinge on purine metabolism and inflammatory processes, thereby indirectly impacting the function of LOC100041282 if it is connected to these biological functions. Sorafenib, a RAF kinase inhibitor, and Axitinib, which targets VEGF receptors, can influence cell differentiation, proliferation, and angiogenesis, processes that could be modulated by LOC100041282. Celecoxib, by inhibiting COX-2, could impact the inflammatory response and, by extension, proteins that play a role in inflammation. Manumycin A, Capmatinib, and Oligomycin A target farnesyltransferase, c-Met, and ATP synthase, respectively.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $26.00 $119.00 $213.00 | 27 | |
A tyrosine kinase inhibitor that can block signal transduction pathways, potentially affecting proteins involved in such pathways. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
An mTOR inhibitor that can interrupt downstream signaling pathways involved in cell proliferation and survival. | ||||||
Allopurinol | 315-30-0 | sc-207272 | 25 g | $131.00 | ||
An inhibitor of xanthine oxidase that can affect purine metabolism and potentially influence proteins involved in this pathway. | ||||||
Zileuton | 111406-87-2 | sc-204417 sc-204417A sc-204417B sc-204417C | 10 mg 50 mg 1 g 75 g | $84.00 $307.00 $369.00 $1254.00 | 8 | |
A 5-lipoxygenase inhibitor that can impact leukotriene synthesis, potentially affecting proteins involved in inflammation. | ||||||
Erlotinib, Free Base | 183321-74-6 | sc-396113 sc-396113A sc-396113B sc-396113C sc-396113D | 500 mg 1 g 5 g 10 g 100 g | $87.00 $135.00 $293.00 $505.00 $3827.00 | 42 | |
An epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor that may affect proteins downstream of EGFR signaling. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
A RAF kinase inhibitor that can impact the RAF/MEK/ERK signaling pathway, potentially affecting associated proteins. | ||||||
Manumycin A | 52665-74-4 | sc-200857 sc-200857A | 1 mg 5 mg | $219.00 $634.00 | 5 | |
A farnesyltransferase inhibitor that can prevent the farnesylation of proteins involved in signaling pathways. | ||||||
INCB28060 | 1029712-80-8 | sc-364510 sc-364510A | 10 mg 50 mg | $305.00 $750.00 | ||
A c-Met inhibitor that can disrupt HGF signaling, potentially affecting proteins that are part of this pathway. | ||||||
ABT-199 | 1257044-40-8 | sc-472284 sc-472284A sc-472284B sc-472284C sc-472284D | 1 mg 5 mg 10 mg 100 mg 3 g | $118.00 $337.00 $520.00 $832.00 $1632.00 | 10 | |
A BCL-2 inhibitor that can induce apoptosis, potentially influencing proteins that interact with BCL-2 or are part of its pathway. | ||||||
Oligomycin A | 579-13-5 | sc-201551 sc-201551A sc-201551B sc-201551C sc-201551D | 5 mg 25 mg 100 mg 500 mg 1 g | $179.00 $612.00 $1203.00 $5202.00 $9364.00 | 26 | |
An inhibitor of ATP synthase that can disrupt cellular energy metabolism, potentially affecting proteins linked to this fundamental process. | ||||||